New Hope in the Fight Against Pancreatic Cancer: Four Preclinical Breakthroughs
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most formidable cancers, with a five-year survival rate of just 13%. However, a wave of recent preclinical studies from leading research institutions is charting new paths forward, targeting the disease from multiple angles. These studies, conducted in mouse models and cell lines, explore strategies ranging from blocking inflammatory networks to eliminating precancerous cells entirely.
Study 1: Disarming the Tumor's Support Network
Lead Institution: Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine
Publication: JCI Insight
Key Finding: Researchers identified the IL1RAP receptor as a control point in inflammatory signaling that helps pancreatic cancer resist treatment. Blocking IL1RAP can disrupt the tumor-driven inflammatory network.
The Challenge: Pancreatic cancer is notoriously difficult to treat due to its tumor microenvironment—a complex network of cells that actively supports tumor growth and shields it from chemotherapy and immunotherapy.
The Discovery: Led by Dr. Jashodeep Datta, the research revealed that IL1RAP acts as a central hub, connecting tumor cells, immune cells, and fibroblasts into a coordinated network that sustains treatment resistance.
The Result: By blocking IL1RAP in preclinical models, researchers observed a cascade of positive effects:
- A decrease in immune-suppressive cells
- An increase in T cell activity
- Reduced fibrosis (scarring)
- An improved response to combination therapy
Next Steps: A neoadjuvant clinical trial is already advancing at Sylvester. The trial will combine IL1RAP-targeted therapy with chemoimmunotherapy in patients with operable pancreatic cancer before surgery. Co-author Dr. Peter Hosein noted the trial will evaluate tumors before and after treatment to understand the biological changes.
Funding: Supported by a Translational Research Grant from the V Foundation ($800,000 over four years).
Study 2: A Triple-Drug "Cocktail" Achieves Complete Tumor Regression
Lead Institution: Spanish National Cancer Research Centre (CNIO)
Publication: PNAS (December 2)
Key Finding: A triple-drug combination therapy blocking three signaling pathways simultaneously demonstrated complete and lasting tumor regression in multiple mouse models of pancreatic cancer.
Background: A mutation in the KRAS gene is associated with nearly all pancreatic cancers. This gene normally regulates cell division; when mutated, it remains permanently active, driving uncontrolled growth.
The Resistance Problem: Prior research showed that blocking single KRAS-related pathways could stop the growth of small tumors, but larger tumors adapted by activating other survival mechanisms. Senior author Carmen Guerra's team found that when one growth route was blocked, a protein called STAT3 became highly active, acting as a backup driver.
The Triple-Drug Therapy: The team designed a three-pronged attack to shut down this escape route:
- Daraxonrasib (RMC-6236): Targets KRAS directly.
- Afatinib: An FDA-approved EGFR family inhibitor (for certain lung cancers).
- SD36: A selective degrader of the STAT3 protein.
The Results: The combination was tested in three distinct mouse models (implanted tumors, genetically engineered mice, and human tumor grafts). In all models, the treatment eliminated the tumors, restoring the pancreas to a healthy state. Tumors did not return for at least 200 days (approx. 7 months), far exceeding the durability of most single-drug therapies.
Toxicity: Notably, the triple-drug therapy did not induce severe side effects in mice. However, researchers caution that some drugs, like afatinib, are known to cause skin and gastrointestinal issues in humans. Work is underway to find alternative drugs targeting the same pathways with fewer side effects.
Study 3: Cancer "Interception" – Targeting Lesions Before They Become Tumors
Lead Institution: Perelman School of Medicine at the University of Pennsylvania and Penn Medicine's Abramson Cancer Center
Publication: Science
Key Finding: Using experimental therapies to target microscopic precancerous lesions in the pancreas nearly doubled survival in mouse models compared to treatment initiated after cancer development.
A New Strategy: This approach is called cancer interception. While prevention stops cancer from forming, interception targets the earliest phases of a cell’s progression toward malignancy. This study provides preclinical proof-of-concept that early medical intervention may be far more effective than treatment after diagnosis.
Targeting KRAS Early: Over 90% of pancreatic cancers are driven by KRAS mutations. The team used experimental RAS inhibitors (RMC-9945 and RMC-7977) to target the active form of RAS. Most PDAC tumors originate from microscopic lesions called PanINs (pancreatic intraepithelial neoplasias), which are too small for scans but almost always carry KRAS mutations.
The Results:
- A reduction in precancerous lesions was observed after just 10 days of treatment.
- Long-term treatment with one inhibitor in PanIN-bearing mice tripled the median overall survival time compared to untreated controls.
- Critically, the group treated before tumor development survived nearly twice as long as the group treated only after the tumor had formed.
Future Clinical Trials: The team plans to translate this into a clinical trial for high-risk patients, such as those with:
- A genetic predisposition (BRCA1, BRCA2, or PALB2 mutations)
- Hereditary pancreatitis
- Precancerous pancreatic cysts
Study 4: Exploiting Senescence to Overcome Drug Resistance
Key Finding: Researchers proposed an indirect approach to counter KRAS-driven malignancy by inhibiting CDK4/6, with subsequent EGFR inhibition selectively triggering cell death in senescent cells.
The Rationale: Current KRAS inhibitors often lead to resistance. A proposed indirect approach involves inhibiting CDK4/6, which can restore cell-cycle control and indirectly suppress oncogenic KRAS signaling by activating the tumor suppressor RB1.
The Problem: While CDK4/6 inhibitors efficiently induced cellular senescence (a state where cells stop dividing but don't die) in pancreatic cancer cells, they did not cause sufficient cell death as a monotherapy.
The Resistance Mechanism: The research revealed a paradoxical increase in ERK activity after CDK4/6 inhibition, traced back to activation of the epidermal growth factor receptor (EGFR). This created a pro-survival environment, leading to resistance.
The Combination Strategy: Researchers investigated combining CDK4/6 inhibitors with EGFR-targeting agents (gefitinib or cetuximab). The key was the sequencing: CDK4/6 inhibition first induces senescence, and then EGFR inhibition selectively triggers cell death in these senescent cells—a process called senolysis.
Safety and Translation: Studies showed that CDK4/6 inhibition did not induce detectable senescence in normal tissues, suggesting a favorable safety window. Because this strategy uses existing, clinically approved agents, it is expected to facilitate rapid translation into clinical trials for pancreatic cancer and potentially other refractory malignancies.